Suntrust Banks Inc. cut its stake in Sanofi SA (NYSE:SNY) by 29.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 265,169 shares of the company’s stock after selling 113,015 shares during the period. Suntrust Banks Inc.’s holdings in Sanofi were worth $11,402,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners increased its stake in Sanofi by 6.2% in the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock valued at $431,429,000 after purchasing an additional 503,799 shares during the period. Fisher Asset Management LLC increased its stake in Sanofi by 3.0% in the fourth quarter. Fisher Asset Management LLC now owns 14,500,758 shares of the company’s stock valued at $623,533,000 after purchasing an additional 418,501 shares during the period. Renaissance Group LLC acquired a new position in Sanofi in the third quarter valued at $16,239,000. St. James Investment Company LLC increased its stake in Sanofi by 9.5% in the fourth quarter. St. James Investment Company LLC now owns 1,559,250 shares of the company’s stock valued at $67,048,000 after purchasing an additional 134,883 shares during the period. Finally, BlackRock Inc. increased its stake in Sanofi by 4.6% in the fourth quarter. BlackRock Inc. now owns 3,055,066 shares of the company’s stock valued at $131,368,000 after purchasing an additional 134,115 shares during the period. 9.07% of the stock is owned by hedge funds and other institutional investors.
Sanofi SA (NYSE SNY) opened at $39.74 on Friday. Sanofi SA has a one year low of $38.14 and a one year high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The stock has a market cap of $99,624.78, a PE ratio of 12.66, a PEG ratio of 2.07 and a beta of 0.85.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.07). Sanofi had a return on equity of 37.09% and a net margin of 23.25%. The firm had revenue of $8.69 billion for the quarter, compared to analyst estimates of $8.65 billion. During the same quarter last year, the firm earned $1.25 earnings per share. The company’s revenue was down 2.1% compared to the same quarter last year. research analysts predict that Sanofi SA will post 3.37 EPS for the current year.
The company also recently declared an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be paid a dividend of $1.8609 per share. This represents a dividend yield of 4.72%. This is a positive change from Sanofi’s previous annual dividend of $1.58. The ex-dividend date of this dividend is Wednesday, May 9th. Sanofi’s payout ratio is 30.14%.
SNY has been the topic of a number of recent research reports. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Morgan Stanley lowered shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Finally, Cowen set a $48.00 price target on shares of Sanofi and gave the stock a “hold” rating in a research note on Monday, December 18th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the stock. Sanofi has a consensus rating of “Hold” and an average target price of $49.33.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/23/suntrust-banks-inc-trims-position-in-sanofi-sa-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.